Transplantation · 1999 · 153 citations · 13 references
MedicineInfectious DiseasesPharmacotherapyHepatologyTransplant ImmunologyTransplant SurgeryLiver Transplant ImmunosuppressionLiver Transplant PharmacotherapyLiver TransplantationTransplant PharmacologyViral HepatitisViral Hepatitis TreatmentAdult Liver TransplantationDeceased Donor Liver TransplantationHepatitis B TherapyHepatitis B Virus ProphylaxisHepatitis Treatment After Liver TransplantationImmune Globulin TherapyLamivudine TherapyLiver Transplantation Management
BACKGROUND: The shortage of donor organs occasionally mandates the use of hepatic allografts from anti-HBc+ donors in recipients who are susceptible to de novo hepatitis B virus (HBV) infection. The efficacy of hepatitis B immune globulin and lamivudine to prevent de novo HBV infection in anti-HBs negative recipients of allografts from anti-HBc+ donors has not been investigated. METHODS: After liver transplantation with an allograft from a donor positive for anti-HBc, recipients who were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6 months. After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months. Patients transplanted after 4/1/97 were given lamivudine 150 mg daily starting postoperative day 1. RESULTS: Between 8/14/96 and 6/10/98, 264 orthotopic liver transplants were performed and 16 anti-HBs-, HbsAg- patients received an hepatic allograft from a donor positive for anti-HBc. HBIG mono-therapy was administered to one patient. HBIG and lamivudine combination therapy was administered to 15 patients. Of the 16 patients, 8 were positive only for anti-HBc before transplant, and 8 were naive (anti-HBs-, anti-HBc-). The single patient who received HBIG monotherapy became HbsAg+ at 6 months. All patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-. The average follow-up is 459 days (range 170-754). Two patients died from unrelated causes. CONCLUSIONS: Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in anti-HBs-, HbsAg- recipients of hepatic allografts from anti-HBc+ donors.
13
RC Dickson, JE Everhart, Yue Wei et al. · Gastroenterology · 1997 · 410 citations · Full text
The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ Donors
Michael Wachs, W Amend, Nancy L. Ascher et al. · Transplantation · 1995 · 338 citations
The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ Donors
Michael Wachs, W Amend, Nancy L. Ascher et al. · Transplantation · 1995 · 336 citations